‘Serum’s pneumococcal vaccine will be available by June 2020’
Serum Institute is optimistic that its pneumococcal vaccine will be available in India by June 2020. The vaccine is yet to be approved by the DCGI. But phase-3 trial data…
Category: DCGI
WHO prequalifies Serum’s low-cost pneumococcal vaccine
WHO has prequalified Pune-based Serum Institute’s pneumococcal conjugate vaccine made of 10 serotypes that are widely prevalent and cause pneumonia in Latin America, Africa and Asia. The vaccine will cost…
Editorial: HPV trial – Collusion of the worst kind
When regulators become violators, who is to regulate them? That perplexing question is what arises from the damning report of the Parliamentary Standing Committee that investigated alleged irregularities in the…
Drugs board wants ban on Pioglitazone diabetes drug revoked
The Drugs Technical Advisory Board (DTAB) on Friday recommended revoking the ban on pioglitazone — an oral anti-diabetic drug which was banned on June 18. But the DTAB, which was…
Diabetes drug: ‘Maybe I erred in my judgement’
There is growing evidence that the ban the Union Health Ministry imposed on June 18 on pioglitazone — a widely used anti-diabetes oral drug — was taken with undue haste…
Editorial: More transparent clinical trials
Published in The Hindu on July 24, 2009 The recent decision of the Drugs Controller General of India to make registration of clinical trials mandatory is laudable and comes two…
